Company is still in a strong cash position , multiple trials underway just the wait for data seems endless but the Biotech Gospel is "You can't rush the science" Like many SH could do with some "Interim Data" but we may well see a SH update upon Ninas return ....
Ann: FDA IND Approval for Phase 3 Study of DMX-200 in FSGS, page-11
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.3¢ |
Change
0.003(0.57%) |
Mkt cap ! $250.3M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 46.5¢ | 44.0¢ | $1.260M | 2.800M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 13756 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 52809 | 5 |
View Market Depth
| Last trade - 15.03pm 09/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |